Small-Molecule Targets in Immuno-Oncology.,Cell Chemical Biology

当前位置： X-MOL 学术 › Cell Chem. Bio. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Small-Molecule Targets in Immuno-Oncology.
Cell Chemical Biology ( IF 6.6 ) Pub Date : 2017-09-21 , DOI: 10.1016/j.chembiol.2017.08.019
Dashyant Dhanak ₁ , James P Edwards ₁ , Ancho Nguyen ₂ , Peter J Tummino ₁

Affiliation

Advances in understanding the role and molecular mechanisms underlying immune surveillance and control of (pre)malignancies is revolutionizing clinical practice in the treatment of cancer. Presently, multiple biologic drugs targeting the immune checkpoint proteins PD(L)1 or CTLA4 have been approved and/or are in advanced stages of clinical development for many cancers. In addition, combination therapy with these agents and other immunomodulators is being intensively explored with the aim of improving primary response rates or prolonging overall survival. The effectiveness of cancer immunotherapy with biologics is spurring research in alternate approaches including small-molecule-mediated targeting of intracellular pathways modulating the innate and adaptive immune response. This focus of this review is on some of the key intracellular pathways where the development of a small-molecule therapeutic is attractive, tractable, and potentially synergistic with extracellular biologic-mediated immune checkpoint blockade.

中文翻译：

免疫肿瘤学中的小分子靶标。

在了解免疫监视和控制（恶性）前体的作用和分子机制方面的进展正在彻底改变癌症治疗的临床实践。当前，已经针对多种癌症批准了针对免疫检查点蛋白PD（L）1或CTLA4的多种生物药物和/或处于临床开发的晚期阶段。另外，为了提高主要反应率或延长总生存期，正在积极探索与这些药物和其他免疫调节剂的联合治疗。用生物制剂进行癌症免疫治疗的有效性正在推动其他方法的研究，包括小分子介导的靶向调节固有免疫和适应性免疫应答的细胞内途径的靶向。

更新日期：2017-09-21

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11